Latest News

The management of oligometastatic prostate cancer (PCa) remains controversial, especially following the introduction of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging. To assess whether stereotactic body radiotherapy (SBRT) provides a potential for cure in a selected group of patients with oligometastatic PCa in the PSMA-PET era. This was a prospective, single-centre study of […]

Male carriers of BRCA mutations are at higher risk of developing prostate cancer. Many issues are still unanswered and are currently being studied, including differences between BRCA1 and BRCA2, screening and specific protocols, the role of active surveillance, and the choice of definitive treatment. European urology focus. 2019 May 27 [Epub ahead of print] Daniel […]

There exists a growing debate as to whether multiparametric MRI (mpMRI) with fusion transrectal ultrasound (TRUS) guided prostate biopsy (PBx) alone without standard template is sufficient for evaluation of patients with suspected prostate cancer (PCa). Our objective was to describe our experience with fusion targeted PBx and assess whether it could obviate the need for […]

The Studies of Prostate Ablation Related Energy Devices (SPARED) coordinated registry network (CRN) is a private-public partnership between academic and community urologists, the US Food and Drug Administration (FDA), Medical Device Epidemiology Network (MDEpiNet) and device manufacturers to examine safety and effectiveness of technologies for partial gland ablation (PGA) in men with localized prostate cancer. […]

The combination of axitinib and crizotinib has a manageable safety and tolerability profile, consistent with the profiles of the individual agents when administered as monotherapy.The antitumor activity reported here for the combination axitinib/crizotinib does not support further study of this combination treatment in metastatic renal cell carcinoma given the current treatment landscape. Vascular endothelial growth […]

Pazopanib is an oral multi-targeted tyrosine kinase inhibitor and has been approved for metastatic renal cell carcinoma and advanced soft tissue sarcoma. To the best of our knowledge, pazopanib-induced thyrotoxicosis has never been reported. The patient was a 68-year-old woman with renal cell carcinoma and multiple metastases. Three weeks after pazopanib medication, she felt fatigue […]

The tumor immune microenvironment has become the focus of research in clear cell renal cell carcinoma (ccRCC) due to its important role in immune surveillance post nephrectomy. This study investigates the correlation of tumor infiltrating immune cell characteristics with rates of recurrence following surgery in localized ccRCC. We morphologically identified and scored tumor infiltrating lymphocytes […]

Aim of this study is to evaluate the correlation between European Organization for Research and Treatment of Cancer (EORTC) risk score and neutrophil-lymphocyte ratio (NLR) in patients with non-muscle invasive bladder cancer and the relationship between NLR and risk groups. We retrospectively reviewed data of 212 patients with non-muscle invasive bladder cancer were included in […]

Accumulative researches have demonstrated the critical functions of long non-coding RNAs (lncRNAs) in the progression of malignant tumors, including bladder cancer (BC). Our previous studies showed that lnc-DILC was an important tumor suppressor gene in both liver cancer and colorectal cancer. However, the role of lnc-DILC in BC remains to be elucidated. In the present […]

Neoadjuvant chemotherapy (NAC) is underutilized in the treatment of bladder cancer (BC). To investigate the effect of NAC on the risk of surgical complications for radical cystectomy (RC) in a population-based setting. All radical cystectomies performed in Finland during 2005-2014 were included in the study. Data were collected retrospectively using a web-based data collection platform. […]